Clinical Trial of Qizhu Yuling Prescription in the Prevention and Treatment of Esophagus Cancer

• Status: Recruiting
• Trial end date: 2024-11-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of Qizhu Yuling prescription for postoperative esophagus cancer.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jie Li

Criteria

Inclusion Criteria:

• 1. Esophageal cancer without esophagogastric junction pT1-4aN + M0 (stage IIB-IVA) meeting the diagnostic criteria without recurrence or metastasis;

2. Patients who have completed adjuvant therapy (including adjuvant radiotherapy, adjuvant chemotherapy, adjuvant chemotherapy + radiotherapy) within 6 months after R0 resection for esophageal cancer;

3. ECOG score 0-2;

4. 18-75 years old;

5. Expected survival ≥ 3 months;

6. Subjects voluntarily signed informed consent.

Exclusion Criteria:

• 1. Combined with primary tumor at other sites;

2. Patients complicated with severe primary diseases of heart, cerebral vessels, liver, kidney and hematopoietic system;

3. Patients with mental illness and mental and language disorders;

4. Participation in other clinical trials within 3 months;

5. Patients with known hypersensitivity or intolerance to study drug.